ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 9331099

Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.

Courjal F and 7 others. Cancer Res, 1997. Cited by 215 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Papers, record 9331099. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9331099

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
PubMed
Journal
Cancer Res
PubMed
Year
1997
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
215
iCite
Relative citation ratio, by iCite
3.96
iCite
Revised in PubMed
2026-01-28
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Courjal FF
2Cuny MM
3Simony-Lafontaine JJ
4Louason GG
5Speiser PP
6Zeillinger RR
7Rodriguez CC
8Theillet CC

Source PubMed

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Chromosomes, HumanMajor topic
DNA, NeoplasmMajor topic
Gene AmplificationMajor topic
Adult
Aged
Blotting, Southern
Carcinoma, Ductal, Breast
Carcinoma, Lobular
Chromosome Mapping
DNA Probes
Estrogens
Female
Genes, myc
Genetic Markers
Humans
Middle Aged
Neoplasm Invasiveness
Neoplasms, Hormone-Dependent
Phenotype
Erb-b2 Receptor Tyrosine Kinases

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by102

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 215 citations.

PMIDTitleJournalYearIn PapersSource
40,702,511Comparative analysis of hybrid-SNP microarray and nanopore sequencing for detection of large-sized copy number variants in the human genome.Mol Cytogenet2025https://conductscience.org/library/papers/40702511PubMed
40,665,359Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion.Breast Cancer Res2025https://conductscience.org/library/papers/40665359PubMed
40,511,560The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review).Int J Mol Med2025https://conductscience.org/library/papers/40511560PubMed
39,462,221Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study.Cancer Sci2025https://conductscience.org/library/papers/39462221PubMed
39,417,188Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.Am J Cancer Res2024https://conductscience.org/library/papers/39417188PubMed
37,427,143Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma.Front Oncol2023https://conductscience.org/library/papers/37427143PubMed
37,390,492Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.Oncologist2023https://conductscience.org/library/papers/37390492PubMed
36,385,700Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro.J Pathol2023https://conductscience.org/library/papers/36385700PubMed
35,838,190Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.Cancer Sci2023https://conductscience.org/library/papers/35838190PubMed
35,484,593Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status.BMC Med2022https://conductscience.org/library/papers/35484593PubMed

1 to 10 of 102

See all 102 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ESR12,099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
MYC4,609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9331099

GET https://conductscience.org/api/papers/v1/9331099/cited_by?page=2

API referenceFor AI assistants